Serina Therapeutics Inc (SER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Serina Therapeutics Inc (SER) has a cash flow conversion efficiency ratio of -2.415x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.85 Million) by net assets ($1.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Serina Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Serina Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Serina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Serina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Serina Therapeutics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Serina Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeong Moon Information. Co. Ltd
KQ:033050
|
0.059x |
|
Aqua Corporation Public Company Limited
BK:AQUA
|
0.005x |
|
Leeuwin Metals Ltd
AU:LM1
|
-0.042x |
|
Trimegah Karya Pratama Tbk PT
JK:UVCR
|
0.798x |
|
UMS-Neiken Group Bhd
KLSE:7227
|
0.019x |
|
Mhethanol Co. Ltd.
KO:023150
|
0.177x |
|
Scan Inter PCL
BK:SCN
|
0.030x |
|
A.S. Création Tapeten AG
F:ACWN
|
0.014x |
Annual Cash Flow Conversion Efficiency for Serina Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Serina Therapeutics Inc from 2016 to 2024. View today's stock price for Serina Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $508.00K | $-17.14 Million | -33.734x | -44098.95% |
| 2023-12-31 | $-32.29 Million | $-2.48 Million | 0.077x | -36.04% |
| 2022-12-31 | $-17.32 Million | $-2.08 Million | 0.120x | -36.75% |
| 2021-12-31 | $-11.88 Million | $-2.25 Million | 0.190x | -86.92% |
| 2020-12-31 | $-5.40 Million | $-7.82 Million | 1.449x | +137.31% |
| 2019-12-31 | $2.62 Million | $-10.16 Million | -3.882x | -299.69% |
| 2018-12-31 | $8.23 Million | $-8.00 Million | -0.971x | -28.57% |
| 2017-12-31 | $8.32 Million | $-6.29 Million | -0.755x | -300.60% |
| 2016-12-31 | $-22.38 Million | $-8.43 Million | 0.377x | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more